Shokrollah Elahi

Professor, Faculty of Medicine & Dentistry - Dentistry Dept

Contact Overview Publications

Contact

Professor, Faculty of Medicine & Dentistry - Dentistry Dept

Email: elahi@ualberta.ca
Phone: (780) 492-1336
Address: 7020G Katz Group Centre For Research
11315 - 87 Ave NW

Edmonton AB

T6G 2H5

Overview

Area of Study / Keywords

HIV pathogenesis Cancer Immunotherapy Immunoregulation Immune checkpoints Neonatal immunology Microbiome Cancer

About

Shokrollah Elahi joined the School in 2014. He obtained several degrees from the Tehran University of Medical Sciences, Iran, and his PhD in Immunology from the Newcastle University in Australia. Elahi moved to Canada and did his first post-doctoral fellowship at Vaccine and Infectious Disease Organization (VIDO) followed by the second post-doctoral fellowship at the Center for Infectious Diseases Research affiliated with the University of Washington (Seattle). Later on as a staff scientist, he continued his research in HIV/AIDS pathogenesis. Finally, he moved to The Cincinnati Children's Hospital Medical Centre where he investigated the mechanism underlying the susceptibility of neonates to infectious diseases.

Research

Dr. Shokrollah Elahi is a cellular and molecular immunologist who works on viral pathogenesis, immune regulation and immune system development.

His research is focused on understanding mechanisms underlying immune dysregulation to generate protective therapeutic approaches.

The Elahi lab works on different immune cells but his lab is, in particular, interested in CD8 T cells and why these cells become exhausted in the context of chronic viral infections (e.g. HIV) and cancer. So, Dr. Elahi is working on coaxing the immune system to fight back again tumour cells. His lab works on different types of cancers including viral-associated and non-viral associated solid tumours, and hematological malignancies.

Featured Publications

Elevated ATP via enhanced miRNA-30b, 30c, and 30e downregulates the expression of CD73 in CD8+T cells of HIV-infected individuals

Shahbaz S., Okoye I., Blevins G., Elahi S.

PLoS Pathogens. 2022 March; 18 (3) 10.1371/journal.ppat.1010378

Hematopoietic responses to SARS-CoV-2 infection

Elahi S.

Cellular and Molecular life Sciences . 2022 March; 79 (3) 10.1007/s00018-022-04220-6

Neutrophils promote T-cell activation through the regulated release of CD44-bound Galectin-9 from the cell surface during HIV infection

Dunsmore G., Rosero E.P., Shahbaz S., Santer D.M., Jovel J., Lacy P., Houston S., Elahi S.

PLOS BIOLOGY. 2021 August; 19 (8) 10.1371/journal.pbio.3001387

The quality of sars-cov-2-specific t cell functions differs in patients with mild/moderate versus severe disease, and t cells expressing coinhibitory receptors are highly activated

Shahbaz S., Xu L., Sligl W., Osman M., Bozorgmehr N., Mashhouri S., Redmond D., Rosero E.P., Walker J., Elahi S.

The Journal of Immunology. 2021 August; 207 (4):1099-1111 10.4049/jimmunol.2100446

Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2

Shahbaz S., Xu L., Osman M., Sligl W., Shields J., Joyce M., Tyrrell D.L., Oyegbami O., Elahi S.

Stem Cell Reports . 2021 May; 16 (5):1165-1181 10.1016/j.stemcr.2021.04.001

Differential transcriptional and functional properties of regulatory T cells in HIV-infected individuals on antiretroviral therapy and long-term non-progressors

Clinical and Translational Immunology. 2021 May; 10 (5):e1289 https://doi.org/10.1002/cti2.1289

Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection

Bozorgmehr N., Mashhouri S., Rosero E.P., Xu L., Shahbaz S., Sligl W., Osman M., Kutsogiannis D.J., Macintyre E., O’neil C.R., Elahi S.

mBio. 2021 April; 12 (3) 10.1128/mBio.00384-21

Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia

Bozorgmehr N., Okoye I., Oyegbami O., Xu L., Fontaine A., Cox-Kennett N., Larratt L.M., Hnatiuk M., Fagarasanu A., Brandwein J., Peters A.C., Elahi S.

Journal for Immunotherapy of Cancer . 2021 April; 9 (4) 10.1136/jitc-2020-002189

Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors

Okoye I., Xu L., Motamedi M., Parashar P., Walker J.W., Elahi S.

Journal for Immunotherapy of Cancer . 2020 December; 8 (2) 10.1136/jitc-2020-001849

Shokrollah Elahi

Contact

Professor, Faculty of Medicine & Dentistry - Dentistry Dept

Overview

Area of Study / Keywords

About

Research

Featured Publications

Elevated ATP via enhanced miRNA-30b, 30c, and 30e downregulates the expression of CD73 in CD8+T cells of HIV-infected individuals

Hematopoietic responses to SARS-CoV-2 infection

Neutrophils promote T-cell activation through the regulated release of CD44-bound Galectin-9 from the cell surface during HIV infection

The quality of sars-cov-2-specific t cell functions differs in patients with mild/moderate versus severe disease, and t cells expressing coinhibitory receptors are highly activated

Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2

Differential transcriptional and functional properties of regulatory T cells in HIV-infected individuals on antiretroviral therapy and long-term non-progressors

Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection

Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia

Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors

Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection

Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection

Protective HIV-specific CD8+ T cells evade Treg cell suppression